All lobbying filings

EMERGENT STRATEGIES

EMERGENT STRATEGIES filed a Q1 amendment for ADVAMED:ADVANCED MEDICAL TECHNOLOGY ASSOCIATION on April 21, 2025, reporting $30,000 in lobbying income.

Lobbying for ADVAMED:ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · trade association representing the advanced medical technology industry

All filings by EMERGENT STRATEGIES · Everything ADVAMED:ADVANCED MEDICAL TECHNOLOGY ASSOCIATION has reported

Filing · LD-2 quarterly report Q1 amendment

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Income

$30,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

HADLEY SOSNOFF

Previously held: Legislative Director (ID-1), Legislative Assistant (ID-1), Legislative Correspondent (NY-18), Staff Assistant (NY-18)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Medical/Disease Research/Clinical Labs

Health tax issues and trade Issues related to Small Business Innovation Research Program PAHPA Reauthorization

Taxation/Internal Revenue Code

Issues relating to health tax issues and trade

Computer Industry

Issues related to health data privacy

Trade (domestic/foreign)

Issues related to CHIPS implementation

Medicare/Medicaid

Issues on legislation pertaining to H.R.1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023 Issues on legislation pertaining to S.5349 Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to transitional coverage of emerging technologies

Bills named in this filing 2

H.R. 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
S. 5349
Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.